glp-1 news nov 2025 Retailers across the country are noticing a spike in returns of clothing as more Americans embrace drugs for weight loss. The rate of retail exchanges where shoppers traded clothing for a 2025 ADA Highlights: A New

The report itselfnot a marketing badgeshould be treated as the source record

Whether youre just starting GLP-1 therapy or youve already reached your goal weight, our physician assistants can help your skin look as fit as you feel

Also, both studies had timelines that averaged less than three years, which is a relatively short period for the onset of dementia

The name-brand offerings will likely be more expensive so what's in store for patients

2025: Novo Nordisk announced positive Phase 3 ESSENCE trial results for semaglutide in early Alzheimer's disease, reporting statistically significant slowing of cognitive and functional decline a breakthrough data package that could establish GLP-1 therapy as a neuroprotective agent and open an addressable market of 6.5 million Alzheimer's patients in the U.S

GLP-1 receptor agonists mimic the natural gut hormone GLP-1 to improve insulin release, lower blood sugar, reduce appetite, support weight loss, and decrease inflammation throughout the body. Which conditions can GLP-1 medications help